


Supplemental Material: Use and outcomes of induction therapy in well-matched kidney transplant recipients


Table of Contents

Supplemental Figure 1:2
Supplemental Figure 2:3
Supplemental Figure 3:4
Supplemental Figure 4:5
Supplemental Table 1:6
Supplemental Table 2:7
Supplemental Table 3:9
Supplemental Table 4:10
Supplemental Table 5:11
Supplemental Table 6:12
Supplemental Table 7:13
Supplemental Table 8:14


Supplemental Figure 1. Time to graft loss from any cause including death (Fig S1A), graft loss censored for death (Fig S1B), and death with a functioning graft (Fig S1C) in zero HLA A, B, DR, DQB1 mismatch first, cPRA > 80, adult kidney only transplant recipients grouped by type of induction therapy. T-cell depleting n=400, IL2-RAs n=56, no induction n=50. Supplemental Table 5 shows the number of patients at risk at various time points after transplantation.




Supplemental Figure 2. Time to graft loss from any cause including death (Fig S2A), graft loss censored for death (Fig S2B), and death with a functioning graft (Fig S2C) in zero HLA A, B, DR, DQB1 mismatch first, DCD donor, adult kidney only transplant recipients grouped by type of induction therapy. T-cell depleting n=101, IL2-RAs n=36, no induction n=20. Supplemental Table 6 shows the number of patients at risk at various time points after transplantation.



Supplemental Figure 3. Time to graft loss from any cause including death (Fig S3A), graft loss censored for death (Fig S3B), and death with a functioning graft (Fig S3C) in zero HLA A, B, DR, DQB1 mismatch first, CIT > 18 hr, adult kidney only transplant recipients grouped by type of induction therapy. T-cell depleting n=697, IL2-RAs n=149, no induction n=104. Supplemental Table 7 shows the number of patients at risk at various time points after transplantation.



Supplemental Figure 4. Graft loss from any cause including death, graft loss censored for death, and death with a functioning graft in zero HLA A, B, DR, DQB1 mismatched first, adult kidney only transplant recipients grouped by type of induction therapy. Thymoglobulin n=1,268, Alemtuzumab n=387, and IL2-RAs /no induction n= 1,287. The p values shown are for the comparison between all three induction groups. The p values from log-rank tests comparing the Thymoglobulin, Alemtuzamb groups are p=0.5, Figure A, p = 0.9, Figure B, p=0.4, Figure C. Supplemental Table 8 show the number of patients at risk at various time points after transplantation.



Supplemental Table 1. Risk Table for Figure 2: A, B, C						
	Time post transplant					
	0 year	1 year	2 years	3 years	4 years	5 years
A. Graft loss from any cause						
T-cell Depleting	1689	1616	1570	1529	1109	754
IL2-RAs	836	810	792	776	581	396
No Induction	451	439	428	421	317	224
B. Death censored graft loss						
T-cell Depleting	1689	1643	1619	1597	1194	827
IL2-RAs	836	822	816	811	620	430
No Induction	451	441	437	435	335	245
C. Death with a functioning graft						
T-cell Depleting	1689	1662	1640	1621	1206	848
IL2-RAs	836	824	812	89	607	419
no Induction	451	449	442	437	336	242

Supplemental Table 2. Association of induction therapy (no induction group as reference) with outcomes of graft loss from any cause death, graft loss censored for death, and death with functioning graft.						
	Graft loss from any cause		Graft loss censored for death		Death with functioning graft	
	Number (%) with Outcome	HR (95% CI)	Number (%) with Outcome	HR (95% CI)	Number (%) With Outcome	HR (95% CI)
Induction Therapy						
No Induction	61 (14)	Reference	28 (6)	Reference	33 (7)	Reference
IL2-RAs	110 (13)	1.01 (0.73-1.38)	47 (6)	0.94 (0.58-1.50)	63 (8)	1.08 (0.71-1.65)
Depleting Antibody	304 (18)	1.19 (0.90-1.58)	163 (10)	1.40 (0.93-2.10)	141 (8)	1.01 (0.69-1.49)
Age at Transplant						
18-39	67 (11)	Reference	56 (9)	Reference	11 (2)	Reference
40-60	125 (14)	1.11 (0.84-1.47)	118 (8)	0.72 (0.52-1.00)	97 (6)	3.08 (1.64-5.78)
61+	193 (23)	1.61 (1.20-2.16)	64 (8)	0.62 (0.42-0.91)	129 (15)	6.42 (3.42-12.06)
Male, Sex	253 (17)	1.31 (1.06-1.61)	124 (8)	1.23 (0.93-1.64)	129 (8)	1.33 (0.99-1.80)
Recipient Race						
White	394 (16)	Reference	194 (8)	Reference	200 (8)	Reference
Black	64 (19)	1.18 (0.90-1.54)	34 (10)	1.20 (0.83-1.75)	30 (9)	1.17 (0.79-1.72)
Other	17 (10)	0.68 (0.42-1.10)	10 (6)	0.84 (0.44-1.59)	7 (4)	0.58 (0.27-1.23)
Diabetes	183 (24)	1.55 (1.28-1.88)	78 (10)	1.30 (0.98-1.73)	105 (14)	1.72 (1.33-2.24)
Insurance						
Medicare	277 (19)	Reference	118 (8)	Reference	159 (11)	Reference
Private	136 (14)	0.91 (0.74-1.13)	79 (8)	1.19 (0.88-1.62)	57 (6)	0.69 (0.51-0.94)
Other	62 (11)	0.87 (0.66-1.17)	41 (7)	1.14 (0.78-1.66)	21 (4)	0.61 (0.38-0.98)
Duration of pre-transplant dialysis	---	1.03 (1.00-1.06)	---	1.00 (0.94-1.05)	---	1.05 (1.01-1.09)

CPRA						
0	203 (14)	Reference	103 (7)	Reference	100 (7)	Reference
1-29	57 (15)	0.89 (0.66-1.20)	27 (7)	0.83 (0.54-1.28)	30 (8)	0.98 (0.65-1.49)
30-79	119 (19)	1.10 (0.86-1.41)	62 (10)	1.11 (0.79-1.56)	57 (9)	1.06 (0.75-1.51)
80-97	63 (19)	1.18 (0.86-1.62)	32 (10)	1.05 (0.68-1.64)	31 (10)	1.33 (0.84-2.11)
98-100	33 (18)	1.08 (0.72-1.62)	14 (8)	0.86 (0.47-1.57)	19 (10)	1.30 (0.75-2.25)
Donor Type						
Living Donor	91 (8)	Reference	49 (5)	Reference	42 (4)	Reference
Deceased Donor KDPI: 0-85	365 (20)	2.08 (1.61-2.69)	182 (10)	2.42 (1.69-3.47)	183 (10)	1.66 (1.15-2.41)
Deceased Donor KDPI: 86-100	19 (30)	3.36 (2.01-5.63)	7 (11)	3.04 (1.33-6.93)	12 (19)	2.77 (1.43-5.39)
* IL2-RAs: Interleukin-2 Receptor Antagonists						

Supplemental Table 3. Risk Table for Figure 3: A, B, C						
	Time post transplant					
	0 year	1 year	2 years	3 years	4 years	5 years
A. Graft loss from any cause: Black recipients						
T-cell Depleting	213	205	199	190	138	93
IL2-RAs / no Induction	130	127	122	119	94	63
B. Graft loss from any cause: Deceased donor recipients						
T-cell Depleting	1255	1190	1150	1119	794	519
IL2-RAs / no Induction	639	611	587	572	409	262
C. Graft loss from any cause: Living donor recipients						
T-cell Depleting	434	426	420	410	315	235
IL2-RAs / no Induction	648	638	633	625	489	358

Supplemental Table 4. Risk Table for Figure 4: A, B, C						
	Time post transplant					
	0 year	1 year	2 years	3 years	4 years	5 years
A. cPRA 0						
T-cell Depleting	661	638	629	612	431	297
IL2-RAs / no Induction	805	777	762	750	568	398
B. cPRA 1-29						
T-cell Depleting	215	214	204	201	141	87
IL2-RAs / no Induction	161	159	153	150	114	78
C. cPRA 30-79						
T-cell Depleting	413	386	369	364	273	180
IL2-RAs / no Induction	215	209	203	197	144	92
D. cPRA 80-97						
T-cell Depleting	258	242	236	225	170	125
IL2-RAs / no Induction	66	65	63	62	45	33
E. cPRA 98-100						
T-cell Depleting	142	136	132	127	94	65
IL2-RAs / no Induction	40	39	39	38	27	19

Supplemental Table 5. Risk Table for Supplemental Figure 1 A,B,C (cPRA > 80%)						
	Time post transplant					
	0 year	1 year	2 years	3 years	4 years	5 years
A. Graft loss from any cause						
T-cell Depleting	400	378	368	352	264	190
IL2-RAs	56	54	53	53	38	26
No Induction	50	50	49	47	34	26
B. Death censored graft loss						
T-cell Depleting	400	388	383	378	292	214
IL2-RAs	56	54	53	53	38	27
No Induction	50	50	49	49	37	29
C. Death with a functioning graft						
T-cell Depleting	400	390	385	374	290	214
IL2-RAs	56	56	56	56	40	28
no Induction	50	50	50	48	37	26

Supplemental Table 6. Risk Table for Supplemental Figure 2 A,B,C (DCD donors)						
	Time post transplant					
	0 year	1 year	2 years	3 years	4 years	5 years
A. Graft loss from any cause						
T-cell Depleting	101	94	89	87	57	32
IL2-RAs	36	34	32	32	22	11
No Induction	20	19	17	17	11	4
B. Death censored graft loss						
T-cell Depleting	101	97	94	93	65	39
IL2-RAs	36	35	35	35	26	14
No Induction	20	20	19	19	12	4
C. Death with a functioning graft						
T-cell Depleting	101	98	96	95	62	35
IL2-RAs	36	35	33	33	23	11
no Induction	20	19	18	18	11	4

Supplemental Table 7. Risk Table for Supplemental Figure 3 A,B,C (Cold ischemic time >18 hours)						
	Time post transplant					
	0 year	1 year	2 years	3 years	4 years	5 years
A. Graft loss from any cause						
T-cell Depleting	697	658	636	617	459	296
IL2-RAs	149	140	135	132	83	46
No Induction	104	100	96	95	73	52
B. Death censored graft loss						
T-cell Depleting	697	670	657	648	497	333
IL2-RAs	149	145	143	143	96	59
No Induction	104	100	98	97	78	56
C. Death with a functioning graft						
T-cell Depleting	697	685	676	666	511	344
IL2-RAs	149	144	141	138	90	53
no Induction	104	104	102	102	80	60

Supplemental Table 8. Risk Table for Supplemental Figure 4: A, B, C						
	Time post transplant					
	0 year	1 year	2 years	3 years	4 years	5 years
A. Graft loss from any cause						
Thymoglobulin	1,268	1,218	1,117	1,141	815	554
Alemtuzumab	387	365	360	356	267	177
IL2-RAs / No Induction	1,287	1249	1220	1197	898	620
B. Death censored graft loss						
Thymoglobulin	1,268	1,238	1,217	1,197	884	610
Alemtuzumab	387	372	369	367	282	193
IL2-RAs / No Induction	1,287	1,263	1,253	1,246	955	675
C. Death with a functioning graft						
Thymoglobulin	1,268	1,248	1,228	1,212	889	625
Alemtuzumab	387	380	378	376	289	200
IL2-RAs / No Induction	1,287	1,273	1,254	1,238	943	661